The recent ruling by the US Food and Drug Administration not to approve ximelagatran(Exanta; AstraZeneca Pharmaceuticals LP, Wilmington, DE) has dimmed the hopes of many practitioners for an easier way to manage oral anticoagulation therapy. Warfarin (Coumadin, Bristol-Myers Squibb Company, New York, NY) consequently remains the only oral anticoagulant available in the United States, and despite its proven efficacy, there are a number of challenging management issues. Recognition of how to manage some of these most challenging aspects of therapy is important in assuring safe and effective therapy.[1,2]
Prog Cardiovasc Nurs. 2005;20(2):80-85. © 2005 Le Jacq Communications, Inc.
© 2007 Prog Cardiovasc Nurs
Cite this: Practical Challenges in the Management of Oral Anticoagulation - Medscape - May 01, 2005.